DYAI Dyadic: קפיטליזציית שוק

The development of the protein synthesis system for vaccines at Dyadic International (DYAI) is funded by reserves, as licensing payments remain unstable and capitalization stands at 0.01. This chart links these expenditures to the unique C1 IT platform, which radically reduces the cost of producing biologics. Meanwhile, the business relies on external contractors for formula creation and clinical testing, remaining a purely scientific hub.

Market capitalization measures the aggregate value of all shares, reflecting investors' current market valuation of the business. The dynamics of this metric allow for the identification of capital consolidation phases and the balance of power among major players. By analyzing the capitalization size of a public company on GURU.Markets, one can determine the potential for long-term scaling. For Dyadic International (DYAI), growth in this metric confirms the value of the C1 platform. The effective reduction of production costs for pharma behemoths grants the company the right to a significant share of the saved funds.